Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

80%(4 trials)

Phase Distribution

Ph phase_3

20%

Ph phase_4

60%

Ph not_applicable

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 3Large-scale testing

1(20.0%)

Phase 4Post-market surveillance

3(60.0%)

N/ANon-phased studies

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 31 (20.0%)

Phase 43 (60.0%)

N/A1 (20.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials

Showing 5 of 5

completednot_applicable

Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings

NCT03751033

completedphase_4

To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

NCT00763360

completedphase_4

Clinical Trials (5)

Showing 5 of 5 trials

NCT03751033Not Applicable

Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings

Completed

NCT00763360Phase 4

To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

Completed

NCT00712244Phase 4

DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus

Completed

NCT00711347Phase 4

Intraoperative Floppy Iris Syndrome

Completed

NCT00732225Phase 3

DisCoVisc Comparative Evaluation

Completed

All 5 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 5